Skip to content

MiNDERA

2 viewers · 30d

Total raised

$25.4M

1 filing since 2024 · latest Debt filed

Cumulative raised
LAST ROUND
Debt · $25.4M
ROUNDS
1
INVESTORS
25
FOUNDED
N/A
HQ
Vista, CA
SECTOR
Healthcare
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

Mindera Health is a precision-medicine diagnostics company in Vista, California that reads the skin transcriptome without a surgical biopsy. Its penny-sized dermal biomarker patch extracts thousands of RNA transcripts in about five minutes, and machine learning models on that data predict which therapies a patient is likely to respond to. Its lead test, Mind.Px, measures roughly 100 mRNA biomarkers to predict a psoriasis patient's response to specific biologic drugs. The company runs a CLIA-certified, CAP-accredited laboratory in the San Diego area.

What sets it apart

Replaces the punch biopsy with an adhesive patch that captures the skin transcriptome painlessly in five minutes, then pairs it with machine learning to predict biologic drug response before an expensive therapy is prescribed.

Funding history

1 round
DebtJan 12, 2024
Form D/A
+$25.4M$25.4M total

Latest SEC filings

via EDGAR · CIK 0001629564
Form D/A · Jan 12, 2024View on EDGAR

Products

1 tracked

Mind.Px

Molecular diagnostic test

A non-invasive predictive diagnostic test for psoriasis. A dermal biomarker patch collects skin RNA in about five minutes, and Mindera's laboratory and machine learning models assess roughly 100 mRNA biomarkers to determine which biologic therapy a patient is likely to respond to.

  • Penny-sized dermal biomarker patch, painless and applied in about five minutes
  • Extracts thousands of RNA transcripts from the skin without a punch biopsy
  • Assesses roughly 100 mRNA biomarkers predictive of biologic drug response
  • Machine learning models trained on patient-specific transcriptome data